Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

Recruiting

Phase 2

Ado-Trastuzumab Emtansine vs. ChemotherapyTesting the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

Sponsor:

NRG Oncology

Code:

NCT05408845

Conditions

Metastatic Salivary Gland Carcinoma

Recurrent Salivary Gland Carcinoma

Stage III Major Salivary Gland Cancer AJCC v8

Stage IV Major Salivary Gland Cancer AJCC v8

Unresectable Salivary Gland Carcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biopsy Procedure

Biospecimen Collection

Computed Tomography

Docetaxel

Echocardiography Test

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-08-19. This information was provided to ClinicalTrials.gov by NRG Oncology on 2025-05-09.